Repare Therapeutics Inc. (RPTX)
| Bid | 1.06 |
| Market Cap | 48.67M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.99 |
| PE Ratio (ttm) | -0.58 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.22 |
| Volume | 324,701 |
| Avg. Volume (20D) | 452,018 |
| Open | 1.15 |
| Previous Close | 1.15 |
| Day's Range | 1.10 - 1.16 |
| 52-Week Range | 1.10 - 8.49 |
| Beta | undefined |
About RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an ora...
Analyst Forecast
According to 3 analyst ratings, the average rating for RPTX stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 511.35% from the latest price.
Next Earnings Release
Analysts project revenue of $2.73M, reflecting a -79.08% YoY shrinking and earnings per share of -0.79, making a 17.91% increase YoY.
2 months ago · businesswire.com
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of CamonsertibCAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib.
